论文部分内容阅读
目的探讨匹多莫德联合孟鲁斯特治疗支气管哮喘患儿的临床疗效。方法选取2013年4月至2014年10月医院收治的支气管哮喘患儿200例,将其采用随机数字表法分为两组,对照组患儿给予常规药物治疗,观察组患儿在对照组基础上采用匹多莫德联合孟鲁斯特治疗。比较两组患儿的治疗效果。结果经治疗后,观察组患儿治疗总有效率为97.0%,明显高于对照组的82.0%,差异有统计学意义(P<0.05);观察组患儿肺功能改善情况明显优于对照组,差异有统计学意义(P<0.05)。观察组患儿治疗出院后发病次数明显少于对照组,且发病持续时间短于对照组,差异均有统计学意义(均P<0.05)。结论匹多莫德联合孟鲁斯特治疗支气管哮喘疗效明显,提高患儿的免疫功能,促进患儿早日康复。
Objective To investigate the clinical efficacy of pidotimod combined with monastus in the treatment of children with bronchial asthma. Methods 200 cases of bronchial asthma admitted from April 2013 to October 2014 in our hospital were selected and divided into two groups according to the random number table. The children in the control group were given conventional drug treatment. The children in the observation group were divided into two groups according to the control group Pidotimod on montelukast treatment. Compare the treatment effect of two groups of children. Results After treatment, the total effective rate in treatment group was 97.0%, which was significantly higher than that in control group (82.0%), the difference was statistically significant (P <0.05); the improvement of pulmonary function in observation group was better than that in control group , The difference was statistically significant (P <0.05). The number of onset of disease in observation group was significantly less than that in control group after discharge, and the duration of onset was shorter than that in control group (all P <0.05). Conclusion Pidotimod montelukast treatment of bronchial asthma significant effect, improve children’s immune function and promote early recovery of children.